Member access

4-Traders Homepage  >  Shares  >  Swiss Exchange  >  Roche Holding Ltd.    ROG   CH0012032048

ROCHE HOLDING LTD. (ROG)

207
 SummaryQuotesChart AnalysisNewsAnalysisCalendarCompanyFinancialsConsensusRevisions 
Quotes 5-day view   End-of-day quote. End-of-day quote Swiss Exchange
12/17/2014 12/18/2014 12/19/2014 12/22/2014 12/23/2014 Date
279(c) 288.7(c) 270.4(c) 273.3(c) 270.1(c) Last
2 531 888 2 136 187 7 906 242 2 253 792 1 561 781 Volume
-0.82% +3.48% -6.34% +1.07% -1.17% Change
More quotes
Company
Roche Holding AG is a leader in research-focused healthcare with combined strengths in pharmaceuticals and diagnostics.As a large biotech company, Roche has truly differentiated medicines in oncology, immunology, infectious diseases, ophthalmology and neuroscience.It is also a leader in in-vitro... 
Sector
Pharmaceuticals
Calendar
01/13Presentation
More about the company
Surperformance© ratings of Roche Holding Ltd.
Trading Rating : Investor Rating :
More Ratings
Chart ROCHE HOLDING LTD.
Duration : Period :
Roche Holding Ltd. Technical Analysis Chart | ROG | CH0012032048 | 4-Traders
Full-screen chart
Financials ( CHF)
Sales 2014 47 314 M
EBIT 2014 17 564 M
Net income 2014 11 708 M
Debt 2014 6 658 M
Yield 2014 3,04%
Sales 2015 49 690 M
EBIT 2015 18 899 M
Net income 2015 12 753 M
Debt 2015 410 M
Yield 2015 3,29%
PER 2014 19,47
PER 2015 17,64
EV / Sales 2014 5,07x
EV / Sales 2015 4,70x
Capitalization 233 082 M
More Financials
Latest news on ROCHE HOLDING LTD.
4d ago ROCHE : FDA Approves Gazyva® (Obinutuzumab) Supplemental Biologics License Appli..
12/19 ROCHE : says agrees to buy Bina Technologies for undisclosed price
12/19DJROCHE : Stops Alzheimer Drug Trial; Shows Mixed Results in Breast Cancer Study
12/19 ROCHE : Genentech : Provides Update on Phase III MARIANNE Study in People with P..
12/18 Roche to pay up to $489 million for next-generation antibody developer
12/17DJFrance Told To Do More for Foreign Investors
12/15 ROCHE : Genentech : Submits New Drug Application to FDA for Investigational Cobi..
12/12DJNOVARTIS : Afinitor Fails to Make a Significant Treatment Difference
More news
Sector news
2h ago AMGEN : Longmont-area's top business stories of 2014
1d ago PFIZER : Miliband needs a pill for headaches posed by foreign takeovers
1d ago GENZYME : FDA reverses course and approves promising yet risky drug to treat MS
More sector news


Comments 
Advertisement
Technical analysis trends
Short TermMid-TermLong Term
TrendsBearishNeutralBullish
Technical analysis
Income Statement Evolution
More Financials
EPS Revisions
More Estimates Revisions
Dynamic quotes  
ON
| OFF